Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | ESRRB | O95718 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28536701 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2ACKR3TLR8CHRM2 | |
| SCHEMBL25507301 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2ACKR3TLR8CHRM2 | |
| SCHEMBL25507694 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2ACKR3TLR8CHRM2 | |
| SCHEMBL12193455 | 0.98 | USP2 (0.47) | USP2SMN1; SMN2ACKR3TLR8CHRM2 | |
| SCHEMBL29215294 | 0.94 | MEN1 (0.44) | USP2SMN1; SMN2ACKR3TLR8CHRM2 | |
| SCHEMBL214593 | 0.94 | USP2 (0.49) | USP2SMN1; SMN2ACKR3TLR8CHRM2 | |
| SCHEMBL8253901 | 0.94 | USP2 (0.51) | USP2SMN1; SMN2ACKR3TLR8CHRM2 | |
| SCHEMBL20873847 | 0.89 | USP2 (0.53) | USP2SMN1; SMN2ACKR3TLR8CHRM2 | |
| SCHEMBL27317678 | 0.88 | MEN1 (0.46) | USP2SMN1; SMN2ACKR3TLR8CHRM2 | |
| SCHEMBL29129466 | 0.88 | TLR8 (0.53) | USP2SMN1; SMN2ACKR3TLR8CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768903-A | Pyrrolo pyrimidine derivative, preparation method thereof, pharmaceutical composition and application | 河北康泰药业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-112574216-B | Compound, preparation method thereof and application thereof in preparing anti-cancer drugs | 天津济坤医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-112574216-A | Compound, preparation method thereof and application thereof in preparing anti-cancer drugs | 天津济坤医药科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2014056852-A1 | LABELED LIGANDS OF THE OXYTOCIN RECEPTOR | UNIVERSITE DE STRASBOURG (FR) | 2014-04-17 | — | — | WO | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| CN-100579957-C | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2010-01-13 | — | — | CN | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| CN-1642906-A | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2005-07-20 | — | — | CN | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | USP2 4155/4885SMN1; SMN2 1381/4885ACKR3 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.